Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a
Thomas C. Darton(Sheffield Teaching Hospitals NHS Foundation Trust), Andrew J. Pollard(University of Oxford), Ben Thompson(Manchester Royal Infirmary), Rebecca Sie(University of Oxford), Brian Angus(University of Oxford), Marcelo B. Sztein(University of Maryland, Baltimore), Anna L. Peters(National Institute for Health and Care Research), Robert A. Kingsley(University of East Anglia), Stephen Lockhart(Johns Hopkins University), Ly‐Mee Yu(Dartmouth–Hitchcock Medical Center), Myron M. Levine(University of Maryland, Baltimore), Catherine A. Jeppesen(University of Oxford), Christoph J. Blohmke, Claire S. Waddington(University of Oxford), Tessa M. John(National Institute for Health and Care Research), Merryn Voysey(Stratasys (Israel)), Christopher Green(UCSF Helen Diller Family Comprehensive Cancer Center), Liqing Zhou(National Institute for Health and Care Research), Kathryn Haworth(National Institute for Health and Care Research), Claire Jones(National Institute for Health and Care Research), Maria Moore(University of Oxford), Gordon Dougan(University of Cambridge), Zoë Hindle(Emergent BioSolutions (United Kingdom))
Cited by 83
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k